Taysha Gene Therapies, Inc. $TSHA Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC lessened its holdings in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 93.3% in the third quarter, Holdings Channel.com reports. The firm owned 32,949 shares of the company’s stock after selling 460,352 shares during the period. SG Americas Securities LLC’s holdings in Taysha Gene Therapies were worth $108,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. AQR Capital Management LLC raised its position in shares of Taysha Gene Therapies by 325.6% in the 1st quarter. AQR Capital Management LLC now owns 107,899 shares of the company’s stock valued at $150,000 after purchasing an additional 82,545 shares in the last quarter. Chicago Partners Investment Group LLC raised its holdings in Taysha Gene Therapies by 40.5% in the second quarter. Chicago Partners Investment Group LLC now owns 163,766 shares of the company’s stock valued at $378,000 after acquiring an additional 47,201 shares in the last quarter. Ethic Inc. bought a new position in Taysha Gene Therapies during the 2nd quarter valued at $67,000. Tybourne Capital Management HK Ltd. grew its holdings in Taysha Gene Therapies by 10.7% during the 2nd quarter. Tybourne Capital Management HK Ltd. now owns 4,095,000 shares of the company’s stock worth $9,459,000 after acquiring an additional 395,000 shares in the last quarter. Finally, May Hill Capital LLC acquired a new position in Taysha Gene Therapies during the 2nd quarter worth $37,000. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on TSHA. Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price target on shares of Taysha Gene Therapies in a research report on Friday, October 17th. Raymond James Financial restated a “strong-buy” rating and set a $13.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, January 6th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 target price on shares of Taysha Gene Therapies in a research report on Friday, November 14th. Wall Street Zen downgraded Taysha Gene Therapies from a “hold” rating to a “sell” rating in a report on Saturday, January 3rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $10.67.

Taysha Gene Therapies Price Performance

Shares of NASDAQ TSHA opened at $4.51 on Friday. The company has a debt-to-equity ratio of 0.23, a current ratio of 10.48 and a quick ratio of 10.48. Taysha Gene Therapies, Inc. has a 1-year low of $1.05 and a 1-year high of $6.02. The business’s fifty day moving average price is $5.12 and its two-hundred day moving average price is $4.11. The firm has a market capitalization of $1.24 billion, a PE ratio of -13.67 and a beta of 1.02.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its earnings results on Tuesday, November 4th. The company reported ($0.09) EPS for the quarter, meeting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. On average, research analysts expect that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year.

Insider Buying and Selling

In other Taysha Gene Therapies news, CFO Kamran Alam sold 78,968 shares of Taysha Gene Therapies stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $4.75, for a total transaction of $375,098.00. Following the transaction, the chief financial officer owned 1,467,635 shares of the company’s stock, valued at $6,971,266.25. The trade was a 5.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Sean P. Nolan sold 136,789 shares of the company’s stock in a transaction on Friday, January 23rd. The stock was sold at an average price of $4.75, for a total transaction of $649,747.75. Following the completion of the transaction, the chief executive officer directly owned 2,949,569 shares in the company, valued at $14,010,452.75. This trade represents a 4.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 967,140 shares of company stock worth $4,510,613 in the last three months. 3.78% of the stock is currently owned by insiders.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.